Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis

Clinical Trials

Volumn 10, Issue 3, 2013, Pages 378-388

  Spineli, Loukia M ^a   Higgins, Julian P T ^b,c   Cipriani, Andrea ^d,e   Leucht, Stefan ^f   Salanti, Georgia ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MILNACIPRAN; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ARTICLE; COMPARATIVE STUDY; HUMAN; INFORMATIVE MISSING ODDS RATIO; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; HUMANS; MARKOV CHAINS; MENTAL DISORDERS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; MONTE CARLO METHOD; ODDS RATIO; TREATMENT OUTCOME; UNCERTAINTY;

EID: 84878252449     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512470317     Document Type: Article

References (23)

1. Tierney FJ, Stewart AL. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol. 2005 ; 34 (1). 79-87
2. Nuesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the analysis in randomised controlled trials: Meta-epidemiological study. BMJ. 2009 ; 339: b3244
3. HigginsPTJAltmanGDSterneACJ. Assessing risk of bias in included studies. In HigginsPTJHollisS (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org
4. White RI, Higgins PTJ, Wood MA. Allowing for uncertainty due to missing data in meta-analysis - Part 1: Two-stage methods. Stat Med. 2008 ; 27 (5). 711-27
5. White RI, Welton JN, Wood MA, et al. Allowing for uncertainty due to missing data in meta-analysis - Part 2: Hierarchical models. Stat Med. 2008 ; 27 (5). 728-45
6. Higgins PTJ, White RI, Wood MA. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clin Trials. 2008 ; 5 (3). 225-39
7. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. J Clin Epidemiol. 2005 ; 58 (6). 579-88
8. Magder SL. Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios, and risk differences. Control Clin Trials. 2003 ; 24 (4). 411-21
9. Hollis S. A graphical sensitivity analysis for clinical trials with non-ignorable missing binary outcome. Stat Med. 2002 ; 21 (24). 3823-34
10. Leon CA, Mallinckrodt HC, Chuang-Stein C, et al. Attrition in randomized controlled clinical trials: Methodological issues in psychopharmacology. Biol Psychiatry. 2006 ; 59 (11). 1001-05
11. Leucht S, Engel RR, Bauml J, et al. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bull. 2007 ; 33 (1). 183-91
12. Mallinckrodt HC, Watkin GJ, Molenberghs G, et al. Choice of the primary analysis in longitudinal clinical trials. Pharm Stat. 2004 ; 3 (3). 161-69
13. Salanti G, Ades EA, Ioannidis PAJ. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J Clin Epidemiol. 2010 ; 64 (2). 163-71
14. Salanti G, Higgins PTJ, Ades EA, Ioannidis PAJ. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008 ; 17 (3). 279-301
15. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet. 2011 ; 378 (9799). 1306-15
16. Cipriani A, Furukawa T, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet. 2009 ; 373 (9665). 746-58
17. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004 ; 23 (20). 3105-24
18. Lunn DJ, Thomas A, Best N, et al. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000 ; 10 (4). 325-37
19. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: The National Academies Press ; 2010 :
20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical principles for clinical trials, Step 5: Note for guidance on statistical principles for clinical trials. International Conference on Harmonization (ICH) Topic E9 ; ;. 23.
21. HelfandMBergAFlumDGabrielSNormandSL. Draft Methodology Report: 'Our questions, our decisions: Standards for patient-centered outcomes research'. Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI) Methodology Committee presented on 23 July 2012, and revised thereafter, 2012.
22. Cipriani A, Geddes JR. What is a run-in phase?. Epidemiol Psichiatr Soc. 2010 ; 19 (1). 21-22
23. Junaidi Stojanovski E, Nur D. Prior sensitivity analysis for a hierarchical model. Proceedings of the Fourth Annual ASEARC Conference, Paper 13, University of Western Sydney ; Paramatta, NSW, Australia ;..